Gland Pharma announced that following the Pre-approval inspection (PAI) for Sterile APIs at the Company's Facility at JNPC, Visakhapatnam between 19 February 2025, and 25 February 2025; the Company has received Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection.